Beneficial Ownership Report · SCHEDULE 13G/A
Repligen Corporation
RGENNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- REPLIGEN CORP
- Company CIK
- 0000730272
- Street
- 41 SEYON STREET
- Street (continued)
- BUILDING 1, SUITE 100
- City
- WALTHAM
- State / country code
- MA
- Postal code
- 02453
Statement details
- Amendment number
- 1
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- FMR LLC
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 7,361,317.84
- Percent of class
- 13.0
- Sole voting power
- 7,345,276.55
- Shared voting power
- 0.00
- Sole dispositive power
- 7,361,317.84
- Shared dispositive power
- 0.00
Reporting person 2
- Name
- Abigail P. Johnson
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 7,361,317.84
- Percent of class
- 13.0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 7,361,317.84
- Shared dispositive power
- 0.00
Item 1
Issuer
REPLIGEN CORP
Principal executive office address
41 SEYON STREET,BUILDING 1, SUITE 100,WALTHAM ,MA,USA,02453
Item 2
Citizenship
Not applicable
Filing person
FMR LLC
Principal business or residence address
245 Summer Street, Boston, Massachusetts 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
13.0
Amount beneficially owned
7361317.84
Sole voting power
Please see the responses to Items 5 and 6 on the cover page.
Shared voting power
0.00
Sole dispositive power
7361317.84
Shared dispositive power
0.00
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of REPLIGEN CORP. No one other person's interest in the COMMON STOCK of REPLIGEN CORP is more than five percent of the total outstanding COMMON STOCK.
Item 7
Not applicable indication
N
Subsidiaries
See attached Exhibit 99.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Please see Exhibit 99 for 13d-1(k) (1) agreement.
Signature comments
* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Signature 1
- Reporting person
- FMR LLC
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
- Date
- 10/06/2026
Signature 2
- Reporting person
- Abigail P. Johnson
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
- Date
- 10/06/2026
Filed exhibits
- EX-99 ↗exhibit99.txt
Company context
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesNov 6, 2026
- 10-Q filingOct 30, 2026
- Unregistered Sales of Equity Securities · Other EventsOct 30, 2026
- Results of Operations and Financial ConditionOct 27, 2026
- Completion of Acquisition or Disposition of Assets · Regulation FD DisclosureOct 6, 2026